Legend Biotech Director Ji Darren Xiaohui Receives 28,330-Share Award

What Happened

• Ji Darren Xiaohui, a director of Legend Biotech Corp (LEGN), was granted 28,330 restricted share units (RSUs) on September 24, 2026. The Form 4 reports the acquisition price as $0.00 per unit (i.e., awarded, not purchased). The award is reported as an "A" (grant/award) on the Form 4 filed September 28, 2026.

Key Details

• Transaction date: 2026-09-24; filing date: 2026-09-28 (filed within the Form 4 deadline).
• Shares/units granted: 28,330 RSUs; reported acquisition price: $0.00.
• Shares owned after transaction: Not specified in the information provided in this summary (not reported here).
• Footnote highlights:
  • F2: These are RSUs; each RSU is a contingent right to one ordinary share upon settlement. 1/3 of the RSUs vest on December 20, 2027; the remaining RSUs vest in 12 equal quarterly installments beginning March 20, 2028, subject to continued service.
  • F1: Legend’s ordinary shares may be represented by ADSs; 1 ADS = 2 ordinary shares.
• Filing timeliness: The Form 4 was filed on 2026-09-28 for the 2026-09-24 transaction (timely under the 2 business-day SEC rule).

Context

• This transaction is a compensation award (RSUs), not an open-market purchase or sale. The reported $0 acquisition price reflects the grant; any economic value to the insider will depend on the company’s share price when and if the RSUs vest and are settled. Such awards are common for executives/directors and primarily reflect compensation rather than a directional personal purchase or sale.